ENDRA Life Sciences to Host Second Quarter 2018 Results Conference Call on Monday, August 13, 2018 at 4:30 p.m. ET

ANN ARBOR, MI / ACCESSWIRE / July 25, 2018 / ENDRA Life Sciences Inc. ("ENDRA") NDRA, a developer of enhanced ultrasound technologies, will hold a conference call on Monday, August 13, 2018 at 4:30 p.m. Eastern time to discuss its results for the three and six months ended June 30, 2018. Financial results will be issued in a press release prior to the call.

ENDRA CEO Francois Michelon, CFO David Wells and CTO Michael Thornton will host the conference call, followed by a question and answer period.

To access the call, please use the following information:

Date: Monday, August 13, 2018
Time: 4:30 p.m. ET, 1:30 p.m. PT
Toll-free dial-in number: 1-877-407-8035
International dial-in number: 1-201-689-8035

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.

The conference call will be broadcast live and available for replay at http://www.investorcalendar.com/event/35753 and via the investor relations section of the Company's website at www.endrainc.com.

A replay of the conference call will be available after 7:30 p.m. Eastern time through August 27, 2018.

Toll-free replay number: 1-877-481-4010
International replay number: 1-919-882-2331
Replay ID: 35753

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. ("ENDRA") NDRA is a developer of enhanced ultrasound technologies. ENDRA's next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) will enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI - at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD), which affects over 1 billion people globally. ENDRA's goal is to bring new capabilities to ultrasound - a $13 billion global market opportunity -- thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.

Company Contact:

David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media & Investor Relations Contact:

MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us

SOURCE: ENDRA Life Sciences Inc.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!